Chapter 32 — Case Study 2: Blood Types, Glycoproteins, and Glycomic Diversity
"If you give the wrong blood type to a patient, the result is hemolytic crisis — and possibly death within minutes. The reason is one sugar at one position. Carbohydrate chemistry can be a matter of life and death." — transfusion medicine text
The ABO blood group system is the most important in transfusion medicine. Discovered by Karl Landsteiner in 1900 (Nobel 1930), it is determined by the presence or absence of specific carbohydrate antigens on red blood cell surfaces. The differences between A, B, AB, and O blood types are encoded in sugar chemistry — specifically, in glycosyltransferase enzymes that add (or fail to add) particular monosaccharides to a common precursor.
This case study explores blood types as a window into the broader world of glycoprotein biology, where carbohydrates serve as cell-surface "barcodes" recognized by the immune system.
The ABO antigens
On the surface of every red blood cell are millions of glycoproteins (and glycolipids) bearing carbohydrate antigens. The ABO system is determined by a specific oligosaccharide attached to one of these surface molecules.
The H antigen (the precursor)
All ABO blood types share a common precursor called the H antigen: a fucose-galactose-N-acetylglucosamine (Fuc-α-1,2-Gal-β-1,3-GlcNAc-...) trisaccharide attached to a lipid or protein anchor. This is what type O cells display.
Type A: H antigen + N-acetylgalactosamine
In type A blood, an enzyme called the A-glycosyltransferase adds an N-acetylgalactosamine (GalNAc) sugar to the H antigen via an α-1,3 linkage. The resulting tetrasaccharide is the A antigen.
Type B: H antigen + galactose
In type B blood, the B-glycosyltransferase adds a galactose (Gal) sugar to the H antigen via the same α-1,3 linkage. The resulting tetrasaccharide is the B antigen.
Type AB: H antigen + GalNAc AND H antigen + Gal
Type AB cells display both the A and the B antigens. The person has both the A-glycosyltransferase and the B-glycosyltransferase genes.
Type O: H antigen alone
In type O blood, the glycosyltransferase gene has a non-functional version (a deletion or null mutation). Neither GalNAc nor Gal is added; only the H antigen is displayed.
The genetic basis
The ABO gene encodes the glycosyltransferase. There are three common alleles: - A allele: codes for an enzyme that uses UDP-GalNAc as the sugar donor → A antigen. - B allele: codes for an enzyme that uses UDP-Gal as the sugar donor → B antigen. - O allele: a deletion in the gene → non-functional enzyme → no sugar added.
The A and B enzymes differ by only 4 amino acids out of 354 — but those 4 amino acids change the active site enough to specifying GalNAc vs Gal substrate preference.
The O allele is recessive (you need two O alleles to be type O).
Immunological consequences: why blood typing matters
The body's immune system makes antibodies against blood-type antigens that the body does NOT have. Specifically: - Type A people: have anti-B antibodies (because they don't display B; the immune system attacks B as foreign). - Type B people: have anti-A antibodies. - Type AB people: have neither anti-A nor anti-B (because they display both antigens; their immune system tolerates both). - Type O people: have both anti-A and anti-B antibodies (because they display neither; their immune system attacks both as foreign).
If a transfusion mismatch occurs (e.g., type A blood given to a type B patient), the recipient's anti-A antibodies attack the donor blood's A antigens. This causes: - Agglutination: red cells clump together. - Hemolysis: red cells burst, releasing hemoglobin into plasma. - Hemolytic shock: kidney damage from hemoglobin overload, blood pressure collapse, death within minutes if not treated.
This is why blood typing is mandatory before any transfusion. The chemistry of sugars is, literally, life or death.
Universal donor and recipient
- Type O is the universal donor for red blood cells: type O cells display only the H antigen, which everyone has. (A or B antibodies in the recipient won't recognize H.)
- Type AB is the universal recipient: AB people have neither anti-A nor anti-B antibodies, so they can receive A, B, AB, or O blood.
These are simplifications — the Rh factor (a separate antigen system) and minor blood groups also matter — but the ABO logic is essentially correct for emergency transfusion.
Beyond ABO: the Lewis, P, and other systems
Many other glycoprotein-based blood antigen systems exist: - Lewis blood group: determined by fucosyltransferases acting on the H precursor. - P blood group: a different glycan class. - MN blood group: based on glycoprotein backbone differences.
Many minor differences are clinically less important but can cause issues in repeat transfusions or pregnancy.
Glycomic diversity: cells write codes in sugars
Beyond blood types, cell-surface glycans are used throughout biology as recognition codes:
Lectins (sugar-binding proteins)
Lectins are proteins that bind specific glycan structures. They mediate: - Cell-cell recognition (e.g., embryonic development, immune signaling). - Pathogen attachment (many bacteria and viruses use lectin-like binding). - Cancer biology (tumor cells often have altered glycosylation patterns).
Examples: - Influenza hemagglutinin binds sialic acid on respiratory epithelium → enables viral entry. Antiviral drugs (oseltamivir/Tamiflu) target the related neuraminidase enzyme. - HIV gp120 is heavily glycosylated; the glycans serve as a "shield" against immune detection. - Selectins (immune cells) bind sialyl-Lewis X glycans on inflamed endothelium → control white blood cell trafficking.
Glycoprotein-mediated diseases
Some diseases involve specific glycan pathology: - Congenital disorders of glycosylation (CDG): rare genetic diseases of glycoprotein synthesis; ~140 known types. - Lysosomal storage diseases (e.g., Tay-Sachs, Hurler syndrome): missing enzymes → accumulation of complex glycans. - Cancer glycomics: tumor cells often have altered glycosylation; some drugs target tumor-specific glycans.
Universal blood and synthetic antigens
A research goal: convert any blood type to type O, eliminating the need for blood-type matching in emergencies.
One approach: enzymatically remove the A or B sugars from donor blood. α-galactosidase (an enzyme that removes galactose) can convert type B → type O. Specific N-acetylgalactosaminidases can convert type A → type O.
Recent work (2010s-2020s) has identified efficient enzymes (sometimes from gut bacteria) that can do this conversion at near-physiological conditions. If perfected, this would create "universal blood" stockpiles for emergency use.
The complete glycomic picture
The total set of glycans on a cell or in a tissue is the glycome — analogous to the genome, transcriptome, and proteome. Its complexity is staggering: - Up to 10⁸ unique glycan structures possible (vs. ~10⁵ unique proteins in the human proteome). - Glycans determine cell identity, signaling, recognition, trafficking, and immune behavior. - Glycomic technology (mass spectrometry, lectin arrays, NMR) is rapidly maturing.
Understanding the glycome is the next frontier of biology, after the genome and proteome. Carbohydrate chemistry is the foundation.
Take-home
- Blood types A, B, AB, O are determined by oligosaccharide antigens on red blood cell surfaces.
- The differences are: type A adds GalNAc; type B adds galactose; type AB adds both; type O has no addition.
- The chemistry: glycosyltransferase enzymes add specific sugars via α-1,3 glycosidic bonds (Ch 32 chemistry).
- Immunology: antibodies attack the blood-type antigens that are NOT yours, causing hemolytic reactions in transfusion mismatch.
- Type O is the universal donor; type AB is the universal recipient.
- Beyond ABO, glycans serve as cell-surface "barcodes" used throughout biology for cell recognition, immune signaling, and pathogen attachment.
- Understanding the glycome is the next frontier in biology, building on the chemistry of Chapter 32.
- Modern research aims to enzymatically convert blood types for emergency use, exploiting Chapter 32 chemistry at clinical scale.